Income Statement Balance Sheet Cash Flow Statement
Annual Financials for MabVax Therapeutics Holdings Inc.
Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 0 0 0 0 0
Cost of Goods Sold (COGS) incl. D&A - 343,000 10,000 1,000 0
COGS excluding D&A - 0 0 0 0
Depreciation & Amortization Expense 556,000 343,000 10,000 1,000 0
Depreciation - - 10,000 - 0
Amortization of Intangibles - - 0 - 0
Gross Income - (343,000) (10,000) (1,000) 0
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 22.94M 19.93M 12.05M 7.98M 5.24M
Research & Development 12.72M 11.04M 5.57M 3.52M 2M
Other SG&A 10.21M 8.89M 6.48M 4.45M 3.25M
Other Operating Expense 0 0 0 0 0
Unusual Expense 991,000 5.79M 0 0 -
EBIT after Unusual Expense (991,000) (5.79M) 0 0 -
Non Operating Income/Expense 343,000 0 0 0 0
Non-Operating Interest Income 533,000 1.34M 35,000 8,000 11,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 85,000 6,000 0 0 0
Gross Interest Expense 85,000 6,000 0 0 0
Interest Capitalized - - - 0 0
Pretax Income (23.69M) (24.72M) (12.02M) (7.97M) (5.23M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 - -
Income Tax - Deferred Domestic 0 0 0 - -
Income Tax - Deferred Foreign 0 0 0 - -
Income Tax Credits 0 0 0 - -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (23.69M) (24.72M) (12.02M) (7.97M) (5.23M)
Minority Interest Expense 0 0 0 0 0
Net Income (23.69M) (24.72M) (12.02M) (7.97M) (5.23M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (23.69M) (24.72M) (12.02M) (7.97M) (5.23M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (23.69M) (24.72M) (12.02M) (7.97M) (5.23M)
EPS (Basic) (105.60) (110.40) (52.80) (29.12) (9.36)
Basic Shares Outstanding 222,379 223,079 224,746 273,500 560,000
EPS (Diluted) (105.60) (110.40) (52.80) (29.12) (9.36)
Diluted Shares Outstanding 222,379 223,079 224,746 273,500 560,000
EBITDA (22.94M) (19.93M) (12.05M) (7.98M) (5.24M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.